[go: up one dir, main page]

WO2002038156A3 - Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria - Google Patents

Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria Download PDF

Info

Publication number
WO2002038156A3
WO2002038156A3 PCT/US2001/047460 US0147460W WO0238156A3 WO 2002038156 A3 WO2002038156 A3 WO 2002038156A3 US 0147460 W US0147460 W US 0147460W WO 0238156 A3 WO0238156 A3 WO 0238156A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds against
against pathogenic
helicobacter bacteria
fluoroquinolone compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/047460
Other languages
French (fr)
Other versions
WO2002038156A2 (en
Inventor
Alison F Chalker
Heather W Minehart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to EP01985001A priority Critical patent/EP1337252A4/en
Priority to AU2002233995A priority patent/AU2002233995A1/en
Priority to JP2002540739A priority patent/JP2004513147A/en
Priority to US10/416,179 priority patent/US20040023983A1/en
Priority to KR10-2003-7006239A priority patent/KR20030060928A/en
Publication of WO2002038156A2 publication Critical patent/WO2002038156A2/en
Publication of WO2002038156A3 publication Critical patent/WO2002038156A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria.
PCT/US2001/047460 2000-11-10 2001-11-08 Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria Ceased WO2002038156A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01985001A EP1337252A4 (en) 2000-11-10 2001-11-08 Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria
AU2002233995A AU2002233995A1 (en) 2000-11-10 2001-11-08 Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria
JP2002540739A JP2004513147A (en) 2000-11-10 2001-11-08 Methods of using fluoroquinolones against pathogenic Helicobacter bacteria
US10/416,179 US20040023983A1 (en) 2001-11-08 2001-11-08 Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria
KR10-2003-7006239A KR20030060928A (en) 2000-11-10 2001-11-08 Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24709300P 2000-11-10 2000-11-10
US60/247,093 2000-11-10

Publications (2)

Publication Number Publication Date
WO2002038156A2 WO2002038156A2 (en) 2002-05-16
WO2002038156A3 true WO2002038156A3 (en) 2002-07-11

Family

ID=22933518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047460 Ceased WO2002038156A2 (en) 2000-11-10 2001-11-08 Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria

Country Status (5)

Country Link
EP (1) EP1337252A4 (en)
JP (1) JP2004513147A (en)
KR (1) KR20030060928A (en)
AU (1) AU2002233995A1 (en)
WO (1) WO2002038156A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262071B1 (en) * 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
US6331550B1 (en) * 1999-06-29 2001-12-18 Smithkline Beecham Corporation Methods of use of quinolone compounds against anaerobic pathogenic bacteria
US6340689B1 (en) * 1999-06-29 2002-01-22 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11209286A (en) * 1998-01-21 1999-08-03 Kyorin Pharmaceut Co Ltd An anti-H. pylori agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262071B1 (en) * 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
US6331550B1 (en) * 1999-06-29 2001-12-18 Smithkline Beecham Corporation Methods of use of quinolone compounds against anaerobic pathogenic bacteria
US6340689B1 (en) * 1999-06-29 2002-01-22 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1337252A4 *

Also Published As

Publication number Publication date
AU2002233995A1 (en) 2002-05-21
JP2004513147A (en) 2004-04-30
WO2002038156A2 (en) 2002-05-16
KR20030060928A (en) 2003-07-16
EP1337252A4 (en) 2005-06-22
EP1337252A2 (en) 2003-08-27

Similar Documents

Publication Publication Date Title
WO2001051456A3 (en) Antibacterial agents
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
AU2002232558A1 (en) Compounds, compositions and methods for treatment of parasitic infections
AU2002302963A1 (en) Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
MY141780A (en) 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics
MXPA03005673A (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors.
MXPA03009206A (en) 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds.
PT1223935E (en) Use of gemifloxacin compounds against bacteria
AU2001266486A1 (en) New compounds useful as antibacterial agents
AU2001244671A1 (en) Quinolonecarboxylic acid derivative
WO2004098500A3 (en) CARBACEPHEM ss-LACTAM ANTIBIOTICS
EP1561465A3 (en) Methods of use of fluoroquinolone compounds against bacteria
MXPA03004331A (en) Novel carbapenem derivatives.
WO2002038156A3 (en) Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria
PL366629A1 (en) 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds
AU2002365664A1 (en) Quinoline derivatives as antitumour agents
CA2281817A1 (en) Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria
WO2004004646A3 (en) O-derivatized nocathiacin derivatives
AU6947900A (en) Methods of use of fluoroquinolone compounds against bacteria
AU2001279612A1 (en) Substituted polyamine compounds
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
GR1003521B (en) Methods of use of fluoroquinolone compounds against gram positive pathogenic bacteria
AU2001228648A1 (en) Clavams as protease inhibitors
AU2003100222A4 (en) Couplings for rotary drill strings
AU2002333377A1 (en) 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1020037006239

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002540739

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001985001

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037006239

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001985001

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10416179

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642